I wouldn't worry too much: (a) Gilead has had a poop touch with acquisitions like KITE for a ridiculous amount, (b) if basket trial enrollment progresses as swiftly and efficiently as announced and promised, CYDY will reach an adequate valuation despite OTC in the next 3-6 months...